Kazia Therapeutics Limited (NASDAQ: KZIA)
$1.7550
+0.0100 ( +0.29% ) 77.9K
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Market Data
Open
$1.7550
Previous close
$1.7450
Volume
77.9K
Market cap
$7.62M
Day range
$1.7100 - $1.8000
52 week range
$1.7001 - $15.8000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Form 6-K | 2 | Dec 31, 2024 |
| 6-k | Form 6-K | 3 | Dec 11, 2024 |
| 20-f | Annual reports | 145 | Nov 15, 2024 |
| 6-k | Form 6-K | 1 | Nov 12, 2024 |
| 6-k | Form 6-K | 41 | Nov 04, 2024 |
| nt | Quarterly Reports | 1 | Nov 01, 2024 |
| 6-k/a | Form 6-K | 1 | Oct 24, 2024 |
| 6-k | Form 6-K | 1 | Oct 15, 2024 |
| 6-k | Form 6-K | 3 | Oct 02, 2024 |
| 6-k | Form 6-K | 3 | Sep 23, 2024 |